It is with pride and a great sense of accomplishment that I announce that I will retire from my role as President of Innovative Medicines Canada, effective June 13, 2016.
It has been an honour and a privilege to lead such a dynamic organization, composed of talented and dedicated individuals. Together, we have worked tirelessly to improve access to innovative medicines for Canadians and to bring more pharmaceutical innovation to Canada. This has been an exciting challenge, and I am proud of the work we have accomplished.
These 12 years as President of this remarkable organization have left me with too many wonderful memories to count. Over the years we have built, renewed and maintained relationships with outstanding partners and collaborators from across the life sciences spectrum. As a country, we have a lot to be proud of; and I feel blessed that I was able to be a part of Canada’s innovative pharmaceutical industry, working alongside passionate advocates for world-class healthcare.
In the coming weeks and months, our Board of Directors will be hard at work to select a new leader for Innovative Medicines Canada. In the meantime, I look forward to working with them to ensure a seamless transition.
I want to take this opportunity to congratulate our Chair, Michael Tremblay and all members of our Board of Directors, as well as all member company CEOs and employees, and the Innovative Medicines Canada staff for their leadership and dedication. They are committed to helping Canada’s innovative pharmaceutical industry become an active participant in finding solutions towards better health outcomes and, ultimately, improving the lives of patients.
Bookmark and Share